Page last updated: 2024-10-30

labetalol and Dysphagia

labetalol has been researched along with Dysphagia in 1 studies

Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.
labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Potter, J1
Mistri, A1
Brodie, F1
Chernova, J1
Wilson, E1
Jagger, C1
James, M1
Ford, G1
Robinson, T1

Trials

1 trial available for labetalol and Dysphagia

ArticleYear
Controlling hypertension and hypotension immediately post stroke (CHHIPS)--a randomised controlled trial.
    Health technology assessment (Winchester, England), 2009, Volume: 13, Issue:9

    Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Cardiotonic Agents; Cost-Benefit Analysis; Deg

2009